Physician profile
Richi Gray
NPI 1073214540
$2,580.11
in general payments reported to CMS, 2019-2025
22 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,285 · 2024: $950 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,567 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,566.71 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $590.27 | 2023-2025 | |
| Lilly USA, LLC | $355.95 | 2023-2024 | Mounjaro, Emgality, Jardiance |
| Ucb, INC. | $274.47 | 2023-2024 | Rystiggo, Briviact |
| Impel Pharmaceuticals INC. | $232.85 | 2023 | Trudhesa |
| Neurelis, INC. | $210.29 | 2023-2024 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $161.11 | 2023-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $113.28 | 2023-2024 | Ingrezza |
| Lundbeck LLC | $95.47 | 2023-2024 | Rexulti |
| Mylan Specialty L.P. | $77.73 | 2023 | Yupelri |
| Pfizer INC. | $75.57 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.70 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $57.31 | 2023-2024 | Ultomiris |
| Phathom Pharmaceuticals, INC. | $51.20 | 2023-2024 | Voquezna |
| Exact Sciences Corporation | $41.86 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $41.60 | 2024 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.13 | 2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $26.44 | 2023 | |
| Axsome Therapeutics, INC. | $21.00 | 2025 | Auvelity |
| Boston Scientific Corporation | $19.40 | 2023 | |
| Glaxosmithkline, LLC. | $14.61 | 2024 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $14.39 | 2025 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $13.48 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richi Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.